Values First Advisors, Inc. Satsuma Pharmaceuticals, Inc. Transaction History

Values First Advisors, Inc.

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	BUY	$0.7 - $1.07 $0 - $0	0 New	0 $0

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Values First Advisors, Inc. with notifications on news.